mTOR Inhibitor Everolimus (Afinitor): MOA, Side effects, Dose

mTOR inhibitor Everolimus Afinitor trucap hyperglycemia

Novartis’ Afinitor (everolimus) was approved by the FDA on February 26, 2016, for the treatment of adult patients with unresectable, locally advanced or metastatic progressive, well-differentiated non-functional neuroendocrine tumors (NETs) originating from the gastrointestinal or lung areas. Afinitor, also known as everolimus, is a type of medication categorized as an mTOR inhibitor. It is available … Read more